In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.

ABSTRACT:

Background

Tumours consist of heterogeneous cancer cells and are likely to contain drug-tolerant cell subpopulations, causing early relapse. However, treatment strategies to eliminate these cells have not been established.

Methods

We established gastric cancer patient-derived cells (PDCs) to examine the contribution of CD44 splicing variant 9 (CD44v9)-positive cells in gastric cancer drug tolerance. We performed gene expression signature-based in silico screening using JFCR_LinCAGE, our anticancer compound gene expression database and subsequent validation in BALB/c-nu/nu mouse xenograft to identify agents targeting the drug-tolerant cancer cells.

Results

CD44v9-positive cancer cells were enriched among residual cancer cells after treatment with SN-38, an active metab

SUBMITTER: Mashima T 

PROVIDER: S-EPMC6889183 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature